Mersana Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events, sending shares of the company tumbling.
Tag Archive for: Mersana Therapeutics
The company is now focused on analyzing the death and “consider potential next steps for development,” CEO Anna Protopapas said in a statement.